Discover Top 50 Companies in Sexually Transmitted Diseases Diagnostics: Statistics Report Till 2035
RELEASE DATE: Aug 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Sexually Transmitted Diseases Diagnostics Market Size is projected to Grow from USD 2.76 Billion in 2024 to USD 5.97 Billion by 2035, at a CAGR of 8.02 % during the forecast period 2025–2035. Future opportunities in the sexually transmitted diseases diagnostics market include rapid point-of-care testing, AI-based diagnostics, home-based test kits, increased awareness campaigns, and expanding access in emerging markets with rising infection rates.
Introduction
The Sexually Transmitted Diseases (STDs) Diagnostics market refers to the industry focused on the development, production, and distribution of tests and technologies used to detect infections transmitted through sexual contact, such as HIV, chlamydia, gonorrhea, syphilis, and HPV. Key factors driving market growth include the rising global prevalence of STDs, increasing public awareness and screening programs, advancements in diagnostic technologies (such as rapid and molecular testing), and government initiatives promoting early detection and prevention. Additionally, growing demand for home-based testing kits and improved healthcare access in developing regions are further boosting market expansion.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the sexually transmitted diseases diagnostics market.
Sexually Transmitted Diseases Diagnostics Market Size & Statistics
- The Market Size for Sexually Transmitted Diseases Diagnostics was Estimated to be Worth USD 2.76 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 8.02 % between 2025 and 2035.
- The Global Sexually Transmitted Diseases Diagnostics Market Size is Anticipated to Reach USD 5.97 Billion by 2035.
- North America is Expected to generate the highest demand during the forecast period in the sexually transmitted diseases diagnostics market.
- Asia Pacific is Expected to Grow the fastest during the forecast period in the Sexually Transmitted Diseases Diagnostics market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the sexually transmitted diseases diagnostics market.
Contributing factors involve increasing rates of sexually transmitted infections in the impoverished countries of Asia Pacific, along with the economic prosperity in these regions, which facilitates the advancement of STD diagnostics.
North America is expected to generate the highest demand during the forecast period in the sexually transmitted diseases diagnostics market.
A rise in the embrace of high-tech products indicates advancement in the industry. Moreover, during the forecast period, industry expansion will be driven by the introduction of innovative POC testing ideas, public health labs providing trustworthy STD testing options, and insurance support. North America currently possesses a monopoly on the worldwide market for diagnosing sexually transmitted diseases, thanks to public healthcare insurance programs that promote health awareness among the population. The presence of advanced FDA-approved diagnostic tools for STDs also aids in the growth of the market.
Top Key Drivers & Sexually Transmitted Diseases Diagnostics Trends
- Rising Prevalence of STDs Worldwide
The increasing incidence of sexually transmitted diseases globally is a major driver for the STD diagnostics market. According to WHO and CDC reports, millions of new cases of infections like chlamydia, gonorrhea, and syphilis occur annually, especially among young adults and adolescents. This surge is prompting governments and healthcare organizations to implement broader screening programs and awareness campaigns. As infections often go undiagnosed due to stigma or lack of symptoms, demand for more accessible, accurate, and early-stage diagnostic tools is rising. This trend supports market growth across public health institutions, clinics, and home-use diagnostics segments.
- Advancements in Diagnostic Technologies
Rapid technological innovations in molecular diagnostics, point-of-care (POC) testing, and AI-based platforms are significantly accelerating the growth of the STD diagnostics market. Newer methods like nucleic acid amplification tests (NAATs), PCR, and immunoassays offer improved accuracy, speed, and convenience, reducing the need for complex laboratory setups. These innovations enable early and reliable detection of asymptomatic infections, which is crucial for timely treatment and containment. Additionally, the emergence of smartphone-enabled home testing kits and telehealth integration is making diagnostics more accessible and private, especially in remote and underserved areas, further expanding the market's reach.
Top 5 Pharma Startups Tackling Sexually Transmitted Diseases
1. dermadiagnostics – Non-Invasive Diagnostic Patch
A key reason many individuals avoid regular STD testing is the uncomfortable nature of the procedure. Certain sexually transmitted infections (STIs) are infectious and may present symptoms in some individuals many years after they have infected the body. Due to the significance of managing infectious diseases for public health, new pharmaceutical startups are focusing on creating non-invasive testing methods for STDs. The US startup dermadiagnostics offers a non-invasive dermal patch system for healthcare providers to diagnose sexually transmitted infections and cervical cancer. This diagnostic system employs a microneedle-based intradermal patch that identifies asymptomatic STIs and gynecologic cancers. The products of the startup enable doctors and healthcare professionals to accurately test and deliver results on the same day. Dermadiagnostics also offers patient-focused diagnostics in gynecologic health.
2. SOA-Test – At-Home STI Diagnostics
Submitting official documents and an unwillingness to talk openly about sexual activity further discourages individuals, particularly younger groups, from undergoing STI testing. This inspires new diagnostics firms to create innovative at-home testing options for STDs. Startups employ secure cloud networks to gather, assess, and deliver results to users. The Dutch HealthTech startup SOA-Test provides a simple and private online STI testing service. Users can evaluate and select an appropriate STI test. Users read the STI testing documents and gather their urine samples. Within ten minutes, the startup allows the test to yield results, empowering users to make informed choices regarding their sexual health. SOA-Test includes sexually transmitted diseases like chlamydia, human immunodeficiency virus (HIV), Hepatitis C, and human papillomavirus (HPV), among others.
3. Pharmiva – Antibiotics-Free Bacterial Vaginosis Treatment
Countless women globally experience bacterial vaginosis, which involves an excessive growth of potentially harmful bacteria in some instances. This results in irregularities in vaginal discharge, induces itching or burning sensations in the vagina, and can potentially lead to the acquisition of STIs. Additionally, many women with this condition exhibit no symptoms. This motivates startups focused on women’s health products to create effective solutions for improving vaginal health. Swedish company Pharmiva is employing its patented local drug delivery system Venerol, a thermoactivated formulation derived from natural substances and crystalline lipids. Venerol helps to stabilize compounds that are hydrophilic and hydrophobic, which might otherwise be prone to degradation. The initial medical device offering from the startup, a vaginal mousse, activates slightly below body temperature, coats the mucosal surface, and gradually releases the ingredients upon use.
4. BlueWillow Biologics – Herpes Simplex Virus-2 (HSV-2) Vaccine
HSV-2 is a highly contagious infection that affects almost half a billion people globally. In many cases, carriers tend to be asymptomatic and can be detected only with regular testing. HSV-2, in particular, is caused by sexual intercourse and also affects the genitals. Further, people suffering from HIV may face life-threatening complications if they also contract herpes simplex viruses. Given the scale of the infection prevalence, pharma companies are working to find effective vaccines for both types of HSV. The US-based startup BlueWillow Biologics is currently developing an intranasal nanoemulsion (NE) vaccine that offers protection against
HSV-2. The vaccine allows for both a systemic and mucosal immune response. The mucosal immunity elicited by NE vaccines provides critical protection against STIs at their point of entry. The startup is planning Phase 1 human clinical trials to advance both its prophylactic and therapeutic NE vaccine candidates.
5. CytoDyn – Antiviral Agents for HIV
Despite recent advancements in the availability of lifelong antiretroviral therapy (ART) for HIV autoimmune deficiency syndrome (AIDS), several people still cannot access suitable treatment. Current medication for HIV/AIDS works to prevent viral transmission while helping individual immune systems. With increasing investments, emerging pharma startups are developing novel solutions to fight, and eventually eliminate, HIV/AIDS. The US-based startup Cytodyn is developing Leronlimab (PRO 140), a new class of HIV/AIDS antiviral agents that protect healthy cells from viral infection. This self-injectable, subcutaneous injection for HIV offers advantages over the current treatments that include no serious side effects and serious adverse events (SAEs) related to Leronlimab. In addition, this solution enables enhanced compliance and increases its half-life. Leronlimab is currently awaiting US Food and Drug Administration (FDA) approval, after completing Phase 3 clinical trials.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the sexually transmitted diseases diagnostics market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 17 Companies Leading the Sexually Transmitted Diseases Diagnostics Market
- Abbott
- Aposcience
- BD
- Biocartis
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Cepheid
- Danaher
- DiaSorin
- GenMark Diagnostics, Inc.
- Hologic Inc.
- OraSure Technologies, Inc.
- Qualigen Inc
- Quidel Corporation
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- MedMira Inc.
1. Abbott
Headquarters: Abbott Park, Illinois, USA
Abbott is a global healthcare company dedicated to advancing medical science and innovation across diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. Founded in 1888, Abbott is widely recognized for its leadership in diagnostics, particularly infectious disease testing, including sexually transmitted diseases. Its diagnostics segment offers cutting-edge laboratory and point-of-care testing solutions, such as the ID NOW and Alinity platforms. The company operates in over 160 countries and focuses on delivering affordable and reliable healthcare solutions worldwide. Abbott’s commitment to innovation and global health makes it a leading player in the STD diagnostics and broader healthcare market.
2. Aposcience AG
Headquarters: Vienna, Austria
Aposcience AG is a biotechnology company headquartered in Vienna, Austria, focused on regenerative medicine and diagnostics. It is known for its research and development of cell-free therapies, including diagnostics based on secretome and exosome technologies. While the company primarily works in wound healing and inflammation, it is expanding into advanced diagnostics for various diseases, including infectious and chronic conditions. Aposcience leverages stem cell research to develop novel biomarker-based tests. Though relatively smaller compared to global giants, its innovations in personalized diagnostics and therapeutic solutions have positioned it as a niche player in the European biomedical landscape.
3. BD (Becton, Dickinson and Company)
Headquarters: Franklin Lakes, New Jersey, USA
BD is a leading global medical technology company specializing in diagnostics, biosciences, and medical devices. Established in 1897, BD is renowned for its advanced diagnostic systems used in clinical microbiology, including sexually transmitted disease (STD) testing. Its BD MAX and BD ProbeTec platforms are widely used for molecular diagnostics and automated specimen processing. BD plays a vital role in disease detection, contributing significantly to global health improvement through innovation, education, and healthcare support. With a strong presence in over 190 countries, BD continuously develops cutting-edge technologies aimed at improving diagnostic accuracy and patient outcomes worldwide.
4. Biocartis NV
Headquarters: Mechelen, Belgium
Biocartis is a molecular diagnostics company headquartered in Mechelen, Belgium, known for its proprietary Idylla platform. The Idylla system offers fully automated, real-time PCR testing that delivers rapid and accurate results with minimal user interaction. While primarily focused on oncology diagnostics, Biocartis is expanding its portfolio into infectious diseases, including STDs, by leveraging its platform's flexibility. The company aims to bring high-quality molecular diagnostics closer to the patient by enabling decentralization of testing. Through strategic collaborations and an expanding test menu, Biocartis is playing an emerging role in improving global access to reliable diagnostics.
5. bioMérieux SA
Headquarters: Marcy-l'Étoile, France
bioMérieux SA is a global leader in in vitro diagnostics, headquartered in Marcy-l'Étoile, France. Founded in 1963, the company specializes in clinical and industrial diagnostic solutions, particularly in infectious diseases, including a comprehensive range of STD testing platforms. bioMérieux’s flagship systems, such as VITEK, VIDAS, and FilmArray, provide advanced solutions for microbiology and molecular diagnostics. The company serves laboratories, hospitals, and research institutions in over 160 countries. With a strong focus on antimicrobial resistance and public health, bioMérieux continues to innovate in diagnostics that enhance disease detection, surveillance, and patient care worldwide.
Are you ready to discover more about the sexually transmitted diseases diagnostics market?
The report provides an in-depth analysis of the leading companies operating in the global Sexually Transmitted Diseases Diagnostics market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Abbott.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Aposcience
- BD
- Biocartis
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Cepheid
- Danaher
- DiaSorin
- GenMark Diagnostics, Inc.
- Hologic Inc.
- OraSure Technologies, Inc.
- Qualigen Inc
- Quidel Corporation
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- MedMira Inc.
Conclusion
The sexually transmitted diseases diagnostics market is evolving rapidly, driven by technological advancements, rising infection rates, and a growing global focus on early detection and prevention. Increased demand for point-of-care solutions, home-based testing, and AI-enabled diagnostics is reshaping the landscape, offering more accessible and private options for users. Regional growth is fueled by expanding healthcare access and awareness campaigns, particularly in emerging economies. Leading companies and innovative startups are actively developing cutting-edge solutions to address unmet diagnostic needs. With strong public health support and continuous R&D, the market is poised to transform sexual health management worldwide.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?